YU25500A - Postupak za sintezu analoga nukleozida - Google Patents

Postupak za sintezu analoga nukleozida

Info

Publication number
YU25500A
YU25500A YU25500A YUP25500A YU25500A YU 25500 A YU25500 A YU 25500A YU 25500 A YU25500 A YU 25500A YU P25500 A YUP25500 A YU P25500A YU 25500 A YU25500 A YU 25500A
Authority
YU
Yugoslavia
Prior art keywords
nucleosite
synthesis
analogues
process
method
Prior art date
Application number
YU25500A
Other languages
English (en)
Inventor
Robert William Scott
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13365199P priority Critical
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU25500A publication Critical patent/YU25500A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of products other than chlorine, adipic acid, caprolactam, or chlorodifluoromethane, e.g. bulk or fine chemicals or pharmaceuticals
    • Y02P20/55Synthetic design, e.g. reducing the use of auxiliary or protecting groups

Abstract

Ovaj pronalazak se odnosi na unapredjenje metoda za sintezu nukleozida sa niskim odnosom α:Гџ anomera. Metod sadrži spajanje zaštićenog furanozil halida i odgovarajućeg zaštićenog heterociklusa u prisustvu nukleofilnog polarnog rastvarača i jake baze.[The invention refers to the improvement of the method for nucleosite synthesis with the low ratio of L- B anomeres. Method contents connecting protected furanozile halide and suitable protected heterocycluse in the presence of nucleofile polar solvent and strong base.
YU25500A 1999-05-11 2000-05-03 Postupak za sintezu analoga nukleozida YU25500A (sh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13365199P true 1999-05-11 1999-05-11

Publications (1)

Publication Number Publication Date
YU25500A true YU25500A (sh) 2003-08-29

Family

ID=22459680

Family Applications (1)

Application Number Title Priority Date Filing Date
YU25500A YU25500A (sh) 1999-05-11 2000-05-03 Postupak za sintezu analoga nukleozida

Country Status (22)

Country Link
US (1) US6271370B1 (sh)
EP (1) EP1052264B1 (sh)
JP (1) JP2001011092A (sh)
KR (1) KR100403900B1 (sh)
CN (1) CN1275575A (sh)
AR (1) AR028991A1 (sh)
AT (1) AT291582T (sh)
AU (1) AU3401100A (sh)
BR (1) BR0002089A (sh)
CA (1) CA2307951A1 (sh)
CZ (1) CZ20001710A3 (sh)
DE (1) DE60018833D1 (sh)
HU (1) HU0001843A3 (sh)
ID (1) ID25992A (sh)
IL (1) IL136027D0 (sh)
IN (1) IN186850B (sh)
MX (1) MXPA00004532A (sh)
PL (1) PL340109A1 (sh)
RU (1) RU2200738C2 (sh)
TR (1) TR200001340A2 (sh)
YU (1) YU25500A (sh)
ZA (1) ZA200002263B (sh)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
AU2006244195B2 (en) 2005-05-05 2012-03-15 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
KR101461263B1 (ko) 2005-10-21 2014-11-17 노파르티스 아게 Il-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2664378A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as pi3k lipid kinase inhibitors
KR20090075714A (ko) 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
JP5327762B2 (ja) 2007-12-14 2013-10-30 プルマジェン セラピューティクス(アズマ)リミテッド インドールおよびその治療的使用
US8207178B2 (en) * 2007-12-14 2012-06-26 Ardea Biosciences, Inc. Fused pyrimidines as reverse transcriptase inhibitors
EA201001129A1 (ru) 2008-01-11 2011-02-28 Новартис Аг Пиримидины в качестве ингибиторов киназы
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
WO2010094956A1 (en) 2009-02-17 2010-08-26 Pulmagen Therapeutics (Inflammation) Limited. Triazolopyridine derivatives as p38 map kinase inhibitors
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
WO2011005860A2 (en) * 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
LT2467141T (lt) 2009-08-17 2019-02-11 Intellikine, Llc Heterocikliniai junginiai ir jų panaudojimas
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
KR20140014184A (ko) 2011-02-25 2014-02-05 아이알엠 엘엘씨 Trk 억제제로서의 화합물 및 조성물
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
CA2856803A1 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
WO2013083606A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Kinase inhibitors
MX359200B (es) 2011-12-09 2018-09-19 Chiesi Farm Spa Inhibidores de cinasa.
US9458154B2 (en) 2011-12-09 2016-10-04 Chiesi Farmaceutici S.P.A. Kinase inhibitors
EP2834246A4 (en) 2012-04-03 2015-10-28 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
SG11201408044QA (en) 2012-06-29 2015-01-29 Pfizer NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2014195402A1 (en) 2013-06-06 2014-12-11 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN105745209B (zh) 2013-09-05 2018-10-23 豪夫迈·罗氏有限公司 三唑并吡啶化合物、组合物及其使用方法
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
JP6487921B2 (ja) 2013-12-17 2019-03-20 ファイザー・インク LRRK2阻害薬としての新規の3,4−二置換−1H−ピロロ[2,3−b]ピリジンおよび4,5−二置換−7H−ピロロ[2,3−c]ピリダジン
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
EP3265464A1 (en) 2015-03-04 2018-01-10 H. Hoffnabb-La Roche Ag Triazolopyridine compounds and methods of use thereof
KR20180050407A (ko) 2015-09-14 2018-05-14 화이자 인코포레이티드 LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
WO2017108736A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
WO2017191098A1 (en) 2016-05-05 2017-11-09 F. Hoffmann-La Roche Ag Pyrazole derivatives, compositions and therapeutic use thereof
WO2018046409A1 (en) 2016-09-06 2018-03-15 F. Hoffmann-La Roche Ag 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
EP3562809A1 (en) 2016-12-29 2019-11-06 H. Hoffnabb-La Roche Ag Pyrazolopyrimidine compounds and methods of use thereof
WO2018166993A2 (en) 2017-03-14 2018-09-20 F. Hoffmann-La Roche Ag Pyrazolochlorophenyl compounds, compositions and methods of use thereof
TW201900648A (zh) 2017-05-22 2019-01-01 瑞士商赫孚孟拉羅股份公司 治療性化合物及組成物以及其使用方法
TW201902896A (zh) 2017-05-22 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療化合物及組合物及其使用方法
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2019139714A1 (en) 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0560477B2 (sh) * 1985-03-11 1993-09-02 Nippon Zoki Pharmaceutical Co
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US4859677A (en) 1987-04-17 1989-08-22 University Of Kansas Nucleoside analogues having antiviral activity
US5246931A (en) 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5470857A (en) 1990-09-14 1995-11-28 Marion Merrell Dow Inc. Carbocyclic nucleoside analogs useful as immunosuppressants
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
ZA9203640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
AU3086495A (en) * 1994-08-02 1996-03-04 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazoles
US5659023A (en) 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
US5840743A (en) 1996-01-23 1998-11-24 The Regents Of The University Of Michigan Modified benzimidazole nucleosides as antiviral agents

Also Published As

Publication number Publication date
JP2001011092A (ja) 2001-01-16
HU0001843D0 (en) 2000-07-28
RU2200738C2 (ru) 2003-03-20
AT291582T (de) 2005-04-15
CA2307951A1 (en) 2000-11-11
EP1052264A2 (en) 2000-11-15
DE60018833D1 (de) 2005-04-28
BR0002089A (pt) 2001-01-02
EP1052264A3 (en) 2001-06-13
AU3401100A (en) 2000-11-16
KR100403900B1 (ko) 2003-11-01
IL136027D0 (en) 2001-05-20
PL340109A1 (en) 2000-11-20
EP1052264B1 (en) 2005-03-23
CZ20001710A3 (cs) 2001-09-12
US6271370B1 (en) 2001-08-07
IN186850B (en) 2001-11-24
HU0001843A2 (hu) 2001-06-28
KR20010069193A (ko) 2001-07-23
AR028991A1 (es) 2003-06-04
CN1275575A (zh) 2000-12-06
TR200001340A2 (tr) 2000-12-21
ID25992A (id) 2000-11-16
HU0001843A3 (en) 2001-09-28
ZA200002263B (en) 2001-12-24
MXPA00004532A (es) 2002-03-08

Similar Documents

Publication Publication Date Title
DE60223662D1 (de) Abscheidungsverfahren auf mischsubstraten mittels trisilan
DE60126104D1 (de) Ernährungszusammensetzung und verfahren zur verbesserung der absetzung von proteinen
GB2368017B (en) Apparatus for electrical stimulation of the leg
DE60208165D1 (de) System und verfahren zur gebrauchseinschränkung von schnurlosen telefonen in sich bewegenden fahrzeugen
DE60129432D1 (de) Verfahren zur rückfaltung von proteinen mit freien cysteinresten
DK1401806T3 (da) Benzoylsulfonamider og sulfonylbenzamidiner til anvendelse som antitumormidler
DE69934646D1 (de) System und Verfahren zur dynamischen Zufuhr von gemischtem Gas
DK1140085T3 (da) Azabicycloalkan som CCR5-modulatorer
TWI244920B (en) Compositions for improving fertility
DE60042883D1 (de) Zusammensetzungen und verfahren zur veränderung der gentranskription
DK1213969T4 (da) Metode til overtrækning af levnedsmidler under anvendelse af hydrogeneret isomaltuloseblanding
AT327224T (de) Chinazolinone benutzende verfahren und zusammenstellungen
HK1165638A1 (zh) 用於對地址解析指派名稱的方法
HU0100156A3 (en) Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions
DE69735634D1 (de) Substituierte cyclopentanderivate die als neuramidase-inhibitoren nuetzlich sind
NZ526542A (en) Pyrimidineamines as angiogenesis modulators
ZA200201511B (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents.
MXPA02001497A (es) Derivados de 3-(5)-ureido-pirazol, procedimiento para su preparacion y sus uso como agentes antitumorales.
AT366721T (de) Indolinderivate als progesteron antagonisten
PT1238979E (pt) Compostos heterociclicos fundidos processo de preparacao dos compostos e farmacos que os contem
IL150908D0 (en) Single phase gels and methods for the preparation thereof
DE50015291D1 (de) Verfahren zum Nachweis von N-terminalem proBNP
DE60031033D1 (de) Organisch-anorganischer Verbundwerkstoff und Verfahren zu seiner Herstellung
AU3764300A (en) Invertebrate biogenic amine receptors
HUS1000008I1 (hu) Oldható CTLA4 molekulák alkalmazása reumatoid artritisz kezelésére